Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2014

View Archived Issues

Improving T1D diagnosis using a novel plasmonic gold chip-based sensor

Validation of a multi-component serum biomarker for the diagnosis of EAC

Canadian and U.S. group discloses new RNA oligomers

Celgene patents novel ERK inhibitors

Pneumococcal vaccines prepared at the Children's Medical Center

Novel Hdm2 inhibitors for cancer disclosed by Merck & Co.

Japanese authorities grant additional approval for Victoza in combination with other agents

WIN-1001X herbal extract shows promise in animal models of PD

Pfizer Japan receives additional indication approval for Solu-Medrol

Merck & Co. prepares novel HCV NS5B inhibitors

Ipsen confirms U.S. and E.U. acceptance of filings for Somatuline

Plethora Solutions to license rights to PSD-502 to European partner

GSK's Lamictal approved as monotherapy for epilepsy in Japan

Ablynx signs license agreement with Eddingpharm to develop ozoralizumab

Russian Ebola vaccine shows promise in preclinical studies

African ginger extract improves symptomatology of asthma and allergies in vivo

Exelixis reports topline results from COMET-1 study of cabozantinib

Novo Nordisk to discontinue R&D activities for inflammatory disorders

ReNeuron offers pipeline update

ValiSeek advances VAL-401 through preclinical testing

ZMapp effectiveness as Ebola therapeutic established in NHP

Birken reports results from phase III trials of Oleogel-S10 for partial thickness wounds

Metgluco additional dosage approved for pediatric type 2 diabetes in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...